Evommune (EVMN) vs InflaRx N.V. (IFRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
InflaRx N.V. is the larger company by market cap ($229.9 million vs $225.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVMN | IFRX |
|---|---|---|
| Share price | $6.22 | $1.56 |
| Market cap | $225.74M | $229.89M |
| 1-day change | -5.90% | -1.27% |
| YTD return | -63.67% | +54.46% |
| 1-year return | — | +13.04% |
| 5-year return | — | -36.84% |
| EPS (TTM) | $-3.75 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.20 | $2.95 |
| 52-week low | $6.08 | $0.798 |
| Distance from 52-week high | -81.27% | -47.10% |
| Analyst consensus | buy | none |
| Avg. price target upside | +287.94% | +391.03% |
| Average volume | 675.52K | 799.42K |
| Shares outstanding | 36.29M | 147.37M |
| Employees | 48 | 65 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Evommune
EVMN stock →Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About InflaRx N.V.
IFRX stock →InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
EVMN vs IFRX FAQ
Which is bigger, Evommune or InflaRx N.V.?
InflaRx N.V. (IFRX) is larger, with a market capitalization of $229.89M compared with $225.74M for Evommune (EVMN).
Are Evommune and InflaRx N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.